Target intelligence / Profile preview

Albumin gene (ALB)

Target
ALB
Molecular classification
Genomic safe harbor, Gene locus, Other
01

Overview

The Albumin gene (ALB) locus, located on chromosome 4q13.3, encodes serum albumin, the most abundant protein in human plasma. In the field of genetic medicine, this locus is highly valued as a 'genomic safe harbor' for in vivo gene editing due to its exceptionally high transcriptional activity in hepatocytes. By inserting a promoterless therapeutic transgene (such as those encoding clotting factors, lysosomal enzymes, or metabolic enzymes) into the albumin locus using genome-editing tools like Zinc Finger Nucleases (ZFNs), CRISPR/Cas9, or nuclease-free homologous recombination (e.g., GeneRide), researchers can leverage the powerful endogenous albumin promoter to drive the high-level secretion of therapeutic proteins into the bloodstream.

This 'bio-factory' approach is being investigated for the treatment of various monogenic disorders, including Hemophilia B, Lysosomal Storage Diseases (such as Mucopolysaccharidosis types I and II), and Methylmalonic Acidemia (MMA). While the primary physiological role of the albumin gene is to maintain systemic osmotic pressure and transport hormones, fatty acids, and drugs, its therapeutic utility lies in providing a stable, high-output platform for protein replacement therapy. However, therapeutic challenges include potential off-target genomic cleavage, insertional mutagenesis, immune responses to the viral vectors used for delivery, and serious adverse events such as thrombotic microangiopathy (TMA).

Other names
ALBALB geneSerum albumin locusAlbumin safe harbor4q13.3 locusHuman albumin locus
02

Mechanism of action

Targeted integration of a therapeutic transgene into the endogenous albumin locus via genome editing (e.g., using Zinc Finger Nucleases, CRISPR/Cas9, or nuclease-free homologous recombination) to leverage the high transcriptional activity of the endogenous albumin promoter for systemic protein production.

03

Biological functions

Protein synthesisRegulation of plasma oncotic pressureLigand transportMaintenance of blood pH
04

Disease associations

Hemophilia BMucopolysaccharidosis type IMucopolysaccharidosis type IIAnalbuminemiaFabry diseaseGaucher diseaseHurler syndromeHunter syndromeMethylmalonic acidemia
05

Safety considerations

Off-target genomic cleavageInsertional mutagenesisImmune response to Adeno-associated virus (AAV) vectorsPotential reduction in endogenous albumin productionGenotoxicityThrombotic microangiopathy (TMA)
06

Interacting drugs

3 more in the full profile.

07

Biomarkers

Serum albumin levelsCirculating therapeutic protein levels (e.g., Factor IX, IDUA, IDS, MMUT)Albumin-2A (ALB-2A) fusion proteinVector DNA copy numberLiver transaminases (ALT, AST)

Beyond the preview

Go deeper on Albumin gene (ALB).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Albumin gene (ALB).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call